Abstract:BackgroundPortal hypertension is a key complication of portal hypertension, which is responsible for the development of varices, ascites, bleeding, and hepatic encephalopathy, which, in turn, cause a high mortality and requirement for liver transplantation.AimThis review deals with the present day state-of-the-art preventative treatments of portal hypertension in cirrhosis according to disease stage. Two main disease stages are considered, compensated and decompensated cirrhosis, the first having good prognosis and being mostly asymptomatic, and the second being heralded by the appearance of bleeding or non-bleeding complications of portal hypertension.ResultsThe aim of treatment in compensated cirrhosis is preventing clinical decompensation, the more frequent event being ascites, followed by variceal bleeding and hepatic encephalopathy. Complications are mainly driven by an increase of hepatic vein pressure gradient (HVPG) to values ≥10 mmHg (defining the presence of Clinically Significant Portal Hypertension, CSPH). Before CSPH, the treatment is limited to etiologic treatment of cirrhosis and healthy life style (abstain from alcohol, avoid/correct obesity…). When CSPH is present, association of a non-selective beta-blocker (NSBB), including carvedilol should be considered. NSBBs are mandatory if moderate/large varices are present. Patients should also enter a screening program for hepatocellular carcinoma. In decompensated patients, the goal is to prevent further bleeding if the only manifestation of decompensation was a bleeding episode, but to prevent liver transplantation and death in the common scenario where patients have manifested first non-bleeding complications. Treatment is based on the same principles (healthy life style..) associated with administration of NSBBs in combination if possible with endoscopic band ligation if there has been variceal bleeding, and complemented with simvastatin administration (20-40 mg per day in Child–Pugh A/B, 10–20 mg in Child C). Recurrence shall be treated with TIPS. TIPS might be indicated earlier in patients with: 1) Difficult/refractory ascites, who are not the best candidates for NSBBs, 2) patients having bleed under NSBBs or showing no HVPG response (decrease in HVPG of at least 20% of baseline or to values equal or below 12 mmHg). Decompensated patients shall all be considered as potential candidates for liver transplantation.ConclusionTreatment of portal hypertension has markedly improved in recent years. The present day therapy is based on accurate risk stratification according to disease stage.

Post-allogeneic Hematopoietic Stem Cell Transplantation Portal Hypertension Not Associated with Liver Cirrhosis, Veno-occlusive Disease, or Graft-versus-host Disease: A Case Report

Clinical Characteristics and Prognostic Factors of Nephrotic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation

Evaluation the Risk Factor of Transplantation-Associated Thrombotic Microangiopathy.

The portal hypertension syndrome: etiology, classification, relevance, and animal models

Living donor liver transplantation for idiopathic portal hypertension with focal nodular hyperplasia

Case Report: Oxaliplatin-induced Idiopathic Non-Cirrhotic Portal Hypertension: a Case Report and Literature Review

Computational Fluid Dynamics-Based Blood Flow Assessment Facilitates Optimal Management of Portal Vein Stenosis After Liver Transplantation

Noncirrhotic portal hypertension due to peripheral T-cell lymphoma, not otherwise specified: A case report

Clinical features of extrahepatic portal vein obstruction: Myeloproliferative neoplasms eliminate hypersplenic hematologic changes in extrahepatic portal vein obstruction

Hemangiopericytoma following allogeneic hematopoietic stem cell transplantation in a patient with primary plasma cell leukemia: the first case report and literature review

S4435 Obliterative Portal Venopathy: An Unusual Case of Liver Fibrosis

Autoimmune-mediated thrombocytopenia after allogeneic hematopoietic stem cell transplantation: significance of detecting reticulated platelets and glycoprotein-specific platelet autoantibodies

Portal cavernoma cholangiopathy treated with living donor liver transplantation: a case report and review of the literature

A Rare Case of Extrahepatic Portal Venous Obstruction in a Nine-Year-Old Female and Its Management: A Case Report

Syndrome Inappropriate ADH Secretion after Allogeneic Hematopoietic Stem Cell Transplantation:A Case Report and Literature Review

Tacrolimus-Induced Hepatic Vein Occlusive Disease After Deceased Donor Liver Transplantation: A Case Report

Early detection and management of portal vein thrombosis after hepatic transplantation: A case report

Chronic Inflammatory Demyelinating Polyneuropathy after Allogeneic Hematopoietic Stem Cell Transplantation: a Case Report and Review of the Literature

Intrinsic Causes of Nonfibrotic Portal Hypertension—A Clinicopathologic Review of 56 Patients

Idiopathic Noncirrhotic Portal Hypertension: An Appraisal

Portal Hypertension Resulted from Paroxysmal Nocturnal Hemoglobinuria: a Case Report and Review of Literature.